February 28, 2020 / 12:52 PM / a month ago

BRIEF-KemPharm Reports Q4 Loss Per Share $0.18

Feb 28 (Reuters) - KemPharm Inc:

* KEMPHARM REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

* Q4 LOSS PER SHARE $0.18

* EXPECT RESEARCH AND DEVELOPMENT SERVICES REVENUE TO CONTINUE THROUGH FY 2020

* FOR Q4, REPORTED REVENUE OF $1.4 MILLION FROM RESEARCH & DEVELOPMENT SERVICES VERSUS Q3 REVENUE OF $11.5 MILLION

* KP415 NDA REMAINS ON TRACK FOR Q1 2020 SUBMISSION

* KEMPHARM - MEASURES TAKEN TO REDUCE OPERATING SPEND & RESTRUCTURE DEBT OBLIGATIONS, POTENTIALLY EXTEND CASH RUNWAY INTO, BUT NOT THROUGH, Q1 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below